10,961 results match your criteria Acute Promyelocytic Leukemia


Blood Parameters in Treatment with Arsenic Trioxide in Acute Promyelocytic Leukemia: Systematic Review.

Int J Hematol Oncol Stem Cell Res 2020 Apr;14(2):130-139

Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML). APL is famed with some special blood coagulation disorders such as disseminated intravascular coagulation (DIC). The therapeutic methods of APL contain All Trans Retinoic Acid (ATRA), arsenic trioxide (ATO) or/and chemotherapy. Read More

View Article

Download full-text PDF

Source

PLZF-RAR, NPM1-RAR, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review.

Cancers (Basel) 2020 May 21;12(5). Epub 2020 May 21.

Hospital Universitari I Politècnic La Fe, Department of Hematology, 46-009 Valencia, Spain.

It has been suggested that 1-2% of acute promyelocytic leukemia (APL) patients present variant rearrangements of retinoic acid receptor alpha (RARα) fusion gene, with the promyelocytic leukaemia zinc finger (PLZF)/RAR being the most frequent. Resistance to all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) has been suggested in PLZF/RAR and other variant APLs. Herein, we analyze the incidence, characteristics, and outcomes of variant APLs reported to the multinational PETHEMA (Programa para el Tratamiento de Hemopatias Malignas) registry, and we perform a systematic review in order to shed light on strategies to improve management of these extremely rare diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12051313DOI Listing

An acylhydroquinone derivative produces OXPHOS uncoupling and sensitization to BH3 mimetic ABT-199 (Venetoclax) in human promyelocytic leukemia cells.

Bioorg Chem 2020 May 18;100:103935. Epub 2020 May 18.

Instituto de Química de Recursos Naturales, Universidad de Talca, Chile; Network for Snake Venom Research and Drug Discovery, Santiago, Chile. Electronic address:

Since cancer cells have different mitochondrial bioenergetic requirements than non-cancerous cells, therapeutic inhibition of its mitochondrial functionality continues to be an important target for anticancer drug discovery. In this study, a series of acylhydroquinones with different acyl-chain length, and their chlorinated derivatives, in the aromatic ring, synthesized by Fries rearrangement under microwave irradiation, were evaluated for their anticancer activity in two leukemia cell lines. Findings from the primary and secondary screening of the 18 acylhydroquinones, tested at 5 µM on acute promyelocytic leukemia HL-60 and acute lymphoblastic leukemia CEM cells lines, identified an acylchlorohydroquinone (12) with a highly selective anti-proliferative effect toward HL-60 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2020.103935DOI Listing

Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia.

Blood Adv 2020 May;4(10):2339-2350

Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology, HCFMUSP, University of São Paulo Medical School, São Paulo, Brazil.

The 2017 European LeukemiaNet 2017 acute myeloid leukemia (AML) risk stratification (ELN2017) is widely used for risk-stratifying patients with AML. However, its applicability in low- and middle-income countries is limited because of a lack of full cytogenetic and molecular information at diagnosis. Here, we propose an alternative for risk stratification (the Adapted Genetic Risk [AGR]), which permits cytogenetic or molecular missing data while retaining prognostic power. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001419DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252562PMC

Real-life outcomes of unselected acute promyelocytic leukemia patients: a single-center 14-year experience.

Rom J Intern Med 2020 May 8. Epub 2020 May 8.

Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Turkey.

Background: After the inclusion of all-trans retinoic acid (ATRA) into the treatment of Acute Promyelocytic leukemia (APL), a notable improvement concerning the survival rates of patients with APL has been observed. However, the population-based studies demonstrated that there was no marked improvement in the survival of patients after the 2000s. We aim to describe the clinical response and prognosis of adult patients diagnosed with APL and examine the change in these outcomes by the time period of diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/rjim-2020-0011DOI Listing

[Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation].

Zhonghua Xue Ye Xue Za Zhi 2020 Apr;41(4):297-301

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

To investigate the clinical characteristics and prognosis in adult acute myeloid leukemia (AML) patients with FLT3-ITD and CEBPA double-mutated (CEBPAdm) co-mutation. Clinical data and prognostic factors were retrospectively analyzed in adult AML patients with FLT3-ITD and CEBPAdm co-mutation at The First Affiliated Hospital of Zhengzhou University from January 2016 to September 2018. Among 599 non-acute promyelocytic leukemia (APL) patients, 268 received gene mutation detection, who were divided into 4 groups including 19 FLT3-ITD positive (FLT3-ITD(+)) and CEBPAdm positive (CEBPAdm(+)) cases (group A) , 84 FLT3-ITD(+) and CEBPAdm(-) cases (group B) , 95 FLT3-ITD(-) and CEBPAdm(+) cases (group C) , 70 double negative mutation cases (group D) . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.04.007DOI Listing

Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?

Leuk Res 2020 May 11;94:106356. Epub 2020 May 11.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Hemorrhagic death is the leading cause of treatment failure in acute promyelocytic leukemia (APL). Our ability to identify patients at greatest risk of hemorrhage, and to actively prevent hemorrhage, remains limited. Nevertheless, some data is available to guide contemporary clinical practice and future investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2020.106356DOI Listing

Structure and in vitro Bioactivity against Cancer Cells of the Capsular Polysaccharide from the Marine Bacterium Psychrobacter .

Mar Drugs 2020 May 19;18(5). Epub 2020 May 19.

G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 159/2, Prospect 100 let Vladivostoku, 690022 Vladivostok, Russia.

Psychrobacter KMM 277 is a psychrophilic Gram-negative bacterium that has been isolated from the internal tissues of an ascidian sp. Here, we report the structure of the capsular polysaccharide from P. KMM 277 and its effect on the viability and colony formation of human acute promyelocytic leukemia HL-60 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/md18050268DOI Listing

Biotransformation of arsenic and toxicological implication of arsenic metabolites.

Authors:
Seishiro Hirano

Arch Toxicol 2020 May 20. Epub 2020 May 20.

Center for Health and Environmental Risk Research, National Institute for Environmental Studies, 16-2 Onogawa, Tsukuba, Ibaraki, 305-8506, Japan.

Arsenic is a well-known environmental carcinogen and chronic exposure to arsenic through drinking water has been reported to cause skin, bladder and lung cancers, with arsenic metabolites being implicated in the pathogenesis. In contrast, arsenic trioxide (AsO) is an effective therapeutic agent for the treatment of acute promyelocytic leukemia, in which the binding of arsenite (iAs) to promyelocytic leukemia (PML) protein is the proposed initial step. These findings on the two-edged sword characteristics of arsenic suggest that after entry into cells, arsenic reaches the nucleus and triggers various nuclear events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00204-020-02772-9DOI Listing

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia.

Leuk Lymphoma 2020 May 20:1-9. Epub 2020 May 20.

Washington University Medical School, St. Louis, MO, USA.

Gemtuzumab ozogamicin (GO) remained available to US clinicians through an open-label expanded-access protocol (NCT02312037) until GO was reapproved. Patients were aged ≥3 months with relapsed/refractory (R/R) acute myeloid leukemia (AML), high-risk myelodysplastic syndrome, or acute promyelocytic leukemia (APL), and had exhausted other treatment options. Three hundred and thirty one patients received GO as monotherapy for R/R AML ( 139), combination therapy for R/R AML ( 183), or treatment for R/R APL ( 9). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1742897DOI Listing

Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum.

Br J Haematol 2020 May 19. Epub 2020 May 19.

Department of Haematology, Lewisham and Greenwich NHS Trust.

The diagnosis and management of acute promyelocytic leukaemia (APML) in the context COVID-19 poses a challenge for clinicians. We present a case illustrating this due to the masking of the typical laboratory pattern of APML coagulopathy and the potential heightened risks of thrombosis and differentiation syndrome (DS) when the two conditions are combined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16864DOI Listing

Higher Level of Peripheral Blood CD34 Positive Cells Presented with Unfavorable Prognosis in Intermediate-Low Risk Acute Promyelocytic Leukemia.

Indian J Hematol Blood Transfus 2020 Apr 17;36(2):309-315. Epub 2019 Dec 17.

1Department of Hematology, Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, 210093 People's Republic of China.

Our previous work has demonstrated that some acute promyelocytic leukemia (APL) patients had significantly elevated circulating CD34+ cell count (≥ 10 × 10/L), and these patients with higher CD34+ cell level usually presented with high-risk disease (WBC > 10,000/μL). The aim of this study was to investigate whether circulating CD34+ cell count is a prognostic marker in intermediate-low risk APL patients. In this study, 76 intermediate-low risk APL patients and 56 age-adjusted healthy volunteers were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-019-01232-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229103PMC

Realgar (α-AsS) Treats Myelodysplasic Syndromes through Reducing DNA Hypermethylation.

Chin J Integr Med 2020 May 16. Epub 2020 May 16.

Research Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences and Beijing Key Lab of Traditional Chinese Medicine Pharmacology, Beijing, 100091, China.

DNA hypermethylation is an epigenetic modification that plays a critical role in the oncogenesis of myelodysplastic syndromes (MDS). Aberrant DNA methylation represses the transcription of promotors of tumor suppressor genes, inducing gene silencing. Realgar (α-AsS) is a traditional medicine used for the treatment of various diseases in the ancient time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11655-020-3263-8DOI Listing

ATPR induces acute promyelocytic leukemia cells differentiation and growth arrest by blockade of SHP2/Rho/ROCK1 pathway.

Toxicol Appl Pharmacol 2020 May 15;399:115053. Epub 2020 May 15.

The Key Laboratory of Major Autoimmune Diseases of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China; The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei, Anhui, China. Electronic address:

Acute promyelocytic leukemia (APL) is a form of acute myeloid leukemia with a unique chromosome translocation t (15;17), commonly complicated by a complex coagulopathy. 4-Amino-2-trifuoromethyl-phenyl retinate (ATPR), a novel all-trans retinoic acid (ATRA) derivative, was synthesized by our group and known to possess obvious biological anti-tumor activities. It has previously been shown that ATPR could induce differentiation and inhibit proliferation of APL cells, although the mechanism responsible for this effect was not well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.taap.2020.115053DOI Listing

Cytogenetic profile and outcome of a pediatric acute promyelocytic leukemia patient presenting with isolated isochromosome 17q in absence of RARA rearrangement.

Blood Cells Mol Dis 2020 May 3:102443. Epub 2020 May 3.

Department of Pediatric Oncology, Tata Memorial Hospital, Dr. E. Borges Road, Parel, Mumbai 400012, India; Homi Bhabha National Institute (HBNI), Anushaktinagar, Mumbai 400094, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcmd.2020.102443DOI Listing

Treatment outcomes of patients with acute promyelocytic leukaemia between 2000 and 2017, a retrospective, single centre experience.

Leuk Res 2020 Apr 24;93:106358. Epub 2020 Apr 24.

Department of Molecular Medicine and Pathology, School of Medical Sciences, University of Auckland, Auckland, New Zealand; Department of Pathology and Laboratory Medicine, LabPlus Haematology, Auckland City Hospital, Auckland, New Zealand. Electronic address:

All-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are effective induction therapy for acute promyelocytic leukaemia (APL). However, early thrombo-haemorrhagic complications and mortality remain high. We aimed to investigate how the timing of ATRA initiation and the inclusion of ATO influence patient outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2020.106358DOI Listing

Constituents of the Fruiting Body of Poisonous Mushroom Omphalotus japonicus.

Chem Pharm Bull (Tokyo) 2020 ;68(5):436-442

The United Graduate School of Agricultural Science, Iwate University.

Six new sesquiterpenes, tsukiyols A-C, neoilludin C, and 4-O-methylneoilludins A and B, were isolated from the fruiting body of Omphalotus japonicus (Kawam.) Kirchm. & O. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/cpb.c19-01009DOI Listing
January 2020

Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review.

Int J Pharm 2020 Jun 4;583:119385. Epub 2020 May 4.

Department of Pharmacy, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China. Electronic address:

Arsenic trioxide (AsO), a front-line therapeutic agent against acute promyelocytic leukemia, has a broad spectrum against malignancies. Unfortunately, the clinical application of AsO in treating hematological cancers has not been transformed to solid tumors, for its dose-limited toxicity and undesirable pharmacokinetics. The ordinary AsO loaded nanodrugs (such as liposomes, polymer micelles, albumin-based nanodrugs, and silica-based nanodrugs, etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2020.119385DOI Listing

Cryptic Acute Promyelocytic Leukemia (APL) Presenting as Seizures in an Adolescent.

Ann Clin Lab Sci 2020 Mar;50(2):270-273

Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA.

There are approximately 800 new cases of acute promyelocytic leukemia (APL) in the United States every year. APL is rarely observed in pediatric populations, and accounts for less than 5-10% of all pediatric cases of acute myeloid leukemia (AML). APL typically presents with symptoms related to the pancytopenia such as fatigue due to anemia, bleeding and bruising secondary to thrombocytopenia, and infections attributed to a lack of functioning leukocytes. Read More

View Article

Download full-text PDF

Source

Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.

Cancer 2020 May 4. Epub 2020 May 4.

Department of Medicine, University of Hong Kong, Hong Kong, China.

Background: The role of arsenic trioxide (As O ) in the maintenance of first complete remission (CR1) in acute promyelocytic leukemia (APL) is unclear.

Methods: A total of 129 consecutive adult patients with APL of all risk categories who achieved CR1 with conventional induction (all-trans retinoic acid [ATRA]/daunorubicin) and consolidation (daunorubicin/cytarabine [induction daunorubicin and consolidation omitted for age ≥70 years]) underwent maintenance comprising ATRA (45 mg/m /day), oral As O (10 mg/day), and ascorbic acid (1 g/day) (AAA) for 2 weeks every 2 months for 2 years.

Results: Over a 17-year period from August 1, 2002, to July 31, 2019, 63 men and 66 women (median age, 46 years [range, 18-82 years]) received AAA maintenance, which was already completed in 117 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32937DOI Listing

Evaluation of growth factor independence 1 expression in patients with acute myeloid leukemia.

J Cancer Res Ther 2020 Jan-Mar;16(1):23-27

Laboratory Hematology and Blood Bank Department, Faculty of Paramedical, Shahid Beheshti University of Medical Sciences; HSCT Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Objective: Growth factor independence 1 (GFI1), a transcriptional repressor, is required for hematopoietic stem cell maintenance and self-renewal in addition to controlling differentiation and proliferation of myeloid cells. As murine studies have demonstrated that this transcription factor has a notable role in the initiation and progression of acute myeloid leukemia (AML) disease, the aim of the current study was to investigate and review the influence of GFI1 in human AML cells.

Methods: GFI1 expression levels were measured by means of real-time polymerase chain reaction in 96 primary AML samples which were then compared to gene expression levels observed in 18 healthy subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_129_17DOI Listing

Occurrence of Hematological Malignancy in Long-term Survivors With Advanced Thymic Cancer.

In Vivo 2020 May-Jun;34(3):1511-1513

Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.

Background: Limited information is available on the occurrence of synchronous malignancy in patients with advanced thymic cancer (TC) who have achieved long-term survival due to sequential chemotherapy. Here, we present two cases of hematological malignancies in long-term survivors with advanced TC.

Case Reports: A 56-year-old man underwent surgical resection following the diagnosis of TC with a histological indication of squamous cell carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/invivo.11938DOI Listing
February 2020

Novel reciprocal fusion genes involving HNRNPC and RARG in acute promyelocytic leukemia lacking RARA rearrangement.

Haematologica 2020 Apr 30. Epub 2020 Apr 30.

Department of Haematology, Qilu Hospital, Cheeloo College of Medcine, Shandong University, Jinan, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.244715DOI Listing
April 2020
5.868 Impact Factor

Combinatorial Low Dose Arsenic Trioxide and Cisplatin Exacerbates Autophagy via AMPK/STAT3 Signaling on Targeting Head and Neck Cancer Initiating Cells.

Front Oncol 2020 15;10:463. Epub 2020 Apr 15.

Institute of Oral Biology, National Yang-Ming University, Taipei, Taiwan.

Head and neck squamous cell carcinoma (HNSCC) is a highly lethal disease with high-level of epidemic both in the world and Taiwan. Previous studies support that head and neck cancer-initiating cells (HN-CICs), a subpopulation of cancer cells with enhanced stemness properties, contribute to therapy resistance and tumor recurrence. Arsenic trioxide (AsO; ATO) has shown to be an effective anti-cancer drug targeting acute promyelocytic leukemia (APL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00463DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174769PMC

JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL).

Int J Hematol 2020 Jun 28;111(6):747-760. Epub 2020 Apr 28.

Department of Hematology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-020-02884-zDOI Listing

Effect of daunorubicin on acute promyelocytic leukemia cells using nuclear magnetic resonance spectroscopy-based metabolomics.

Environ Toxicol Pharmacol 2020 Apr 3;78:103382. Epub 2020 Apr 3.

Department of Hematology, The Affiliated Hospital of Gulin Medical University, Guilin, China. Electronic address:

The aim of this study was to determine several key metabolites as potential biomarkers of daunorubicin (DNR) treatment of acute promyelocytic leukemia (APL) using APL blasts and NB4 cells. Samples which were obtained from 16 newly diagnosed APL patients and human APL NB4 cell lines were exposed to increasing concentrations of DNR (0 μM, 0.1 μM, 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.etap.2020.103382DOI Listing

Tetraploid/near-tetraploid acute promyelocytic leukaemia with double (15;17) translocation.

Malays J Pathol 2020 Apr;42(1):127-130

University Malaya Medical Centre, Department of Pathology, Division of Laboratory Medicine, kuala Lumpur, Malaysia.

A 57-year-old man presented with intermittent fever and bleeding following dental surgery. Peripheral smear and bone marrow aspirate exhibited unusually large and bizarre-looking abnormal cells which were found to be myeloblasts with aberrant CD56 and CD2 expression on immunophenotyping. Fluorescence in situ hybridization analysis revealed an extra RARA gene rearrangement. Read More

View Article

Download full-text PDF

Source

Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.

Clin Lymphoma Myeloma Leuk 2019 Oct 14. Epub 2019 Oct 14.

Henan Provincial People's Hospital, Institute of Hematology of Henan Provincial People's Hospital, Zhengzhou, Henan, PR China; Henan Provincial People's Hospital, Henan Key Laboratory of Stem Cell Differentiation and Modification, Zhengzhou, Henan, PR China. Electronic address:

Introduction: The purpose of this study was to explore the outcomes of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) as a frontline treatment in adult patients with acute promyelocytic leukemia (APL).

Patients And Methods: We analyzed the outcomes of ATRA and intravenous ATO plus IDA as a frontline induction therapy in 118 patients with APL with high-risk (HR) and standard-risk (SR) disease from January 2008 to December 2017. The medical records of 118 patients with APL (HR, n = 45; SR, n = 73) who received the frontline triple combination regimen at Henan Provincial People's Hospital and Tongji Hospital were retrospectively reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.10.003DOI Listing
October 2019

Osteonecrosis of the jaw induced by arsenic trioxide therapy in a leukemia patient: A rare case report and literature review.

Oral Oncol 2020 Apr 21:104725. Epub 2020 Apr 21.

Odontology Department, Regional University Hospital of Nancy, 5 rue du Morvan, 54500 Vandoeuvre-lès-Nancy, France; Department of Oral Surgery, Faculty of Odontology, Lorraine University, 7 avenue de la forêt de Haye, 54505 Vandoeuvre les Nancy, France. Electronic address:

A patient suffering from acute promyelocytic leukemia (APL) was referred to the dental department before introduction of chemotherapy by all-trans retinoic acid and arsenic trioxide (ATO). A panoramic radiography showed his third upper maxillary left tooth included into the maxillary bone. The patient presented with a febrile episode. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2020.104725DOI Listing

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).

Blood Adv 2020 Apr;4(8):1683-1689

Fred Hutchinson Cancer Research Center, Seattle, WA.

High-risk acute promyelocytic leukemia (APL) remains a therapeutic challenge, with higher associated rates of early mortality and relapse than standard-risk APL. All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) is a well-established treatment for patients with standard-risk APL, but it is not well defined for those with high-risk APL. In a prior study of patients with high-risk APL, the addition of gemtuzumab ozogamicin (GO) to ATO plus ATRA suggested benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189292PMC

ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity.

Adv Sci (Weinh) 2020 Apr 27;7(8):1902130. Epub 2020 Feb 27.

Institute of Virology School of Medicine Technical University of Munich 85764 Munich Germany.

Human adenoviruses (HAdV) are associated with clinical symptoms such as gastroenteritis, keratoconjunctivitis, pneumonia, hepatitis, and encephalitis. In the absence of protective immunity, as in allogeneic bone marrow transplant patients, HAdV infections can become lethal. Alarmingly, various outbreaks of highly pathogenic, pneumotropic HAdV types have been recently reported, causing severe and lethal respiratory diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/advs.201902130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175289PMC

Clinical significance of increased PML-RARa transcripts after induction therapy for acute promyelocytic leukaemia.

Ann Med 2020 Apr 23:1-6. Epub 2020 Apr 23.

Department of Hematology, Tongji Hospital, Tongji Medical College, Hua Zhong University of Science and Technology, Wu Han, Hubei, China.

To analyze the clinical and biological significance of the acute promyelocytic leukemia (APL) whose PML-RARa transcripts increased after induction therapy. We analyzed 9 cases of APL whose PML-RARa transcripts increased after induction treatment and compare them with APL whose PML-RARa transcripts decreased. The only factor affecting increased PML-RARa transcripts was the induction protocol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07853890.2020.1753886DOI Listing

[Tetrandrine Induces HL-60 Cell Differentiation].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2020 Apr;28(2):400-404

Department of Pediatrics, The Second Affiliated Hospital, University of South China, Hengyang 421001, Hunan Province, ChinacE-mail:

Objective: To investigate the differentiation of acute promyelocytic leukemia (APL) cells induced by Tetrandrine targeting MUC1.

Methods: HL-60 cells at logarithmic growth phase were choosen as object of reaserch and were divided into four groups: control, ATRA, Tetrandrine and ATRA+Tetrandrine group. Cell morphologic changes in each group were observed by microscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2020.02.007DOI Listing

Do exosomes play role in cardiovascular disease development in hematological malignancy?

Mol Biol Rep 2020 Apr 21. Epub 2020 Apr 21.

High Institute for Education and Research in Transfusion Medicine, Tehran, Iran.

Exosomes play a role in the pathogenesis and treatment of malignancies as a double-edged sword. Recently, researchers discussed about two new roles, cardiomyocyte function impairment and cardiovascular disease (CVD) genesis. Data were collected from PUBMED at various time points up to the 2019 academic year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11033-020-05453-zDOI Listing

[Clinical analysis of 10 patients of acute promyelocytic leukemia with a variant RARα translocation].

Zhonghua Xue Ye Xue Za Zhi 2020 Mar;41(3):257-260

Henan Cancer Hospital/the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.03.014DOI Listing

A rare case of acute promyelocytic leukemia with ider(17)(q10)t(15;17)(q22;q21) and favorable outcome.

Mol Cytogenet 2020 10;13:13. Epub 2020 Apr 10.

1Clinical Laboratory, Qindao University Medical College Affiliated Yantai Yuhuangding Hospital, No. 20, Yuhuangding East Road, Yan Tai, 264000 China.

Background: Chromosomal rearrangements in addition to t(15;17) have been reported in 25-40% of APL patients, with a large predominance of trisomy 8. Other abnormalities are far less frequent, particularly as ider(17), and the prognostic significance is still unclear.

Case Presentation: We present the case of a patient with t(15;17)(q22;q21), der(15)t(15;17) and ider(17)(q10)t(15;17)(q22;q21). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13039-020-00479-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149855PMC

Classic and Variants APLs, as Viewed from a Therapy Response.

Cancers (Basel) 2020 Apr 14;12(4). Epub 2020 Apr 14.

Institut National de la Santé et de la Recherche Médicale (INSERM) U944, Equipe Labellisée par la Ligue Nationale contre le Cancer, 75010 Paris, France.

Most acute promyelocytic leukemia (APL) are caused by PML-RARA, a translocation-driven fusion oncoprotein discovered three decades ago. Over the years, several other types of rare X-RARA fusions have been described, while recently, oncogenic fusion proteins involving other retinoic acid receptors (RARB or RARG) have been associated to very rare cases of acute promyelocytic leukemia. PML-RARA driven pathogenesis and the molecular basis for therapy response have been the focus of many studies, which have now converged into an integrated physio-pathological model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12040967DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226009PMC

Acute Promyelocytic Leukemia during Pregnancy: A Systematic Review of the Literature.

Cancers (Basel) 2020 Apr 14;12(4). Epub 2020 Apr 14.

Department of Hematology, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain.

The management of pregnant women with acute promyelocytic leukemia (APL) is a challenging situation where limited evidence-based information is available. We performed a systematic literature review to analyze the outcomes reported for both mother and fetus when APL is diagnosed during pregnancy. PubMed, Scopus and Web of Science databases were systematically searched to identify studies reporting cases of APL during pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12040968DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225915PMC

Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid-induced differentiation.

Sci Adv 2020 04 8;6(15):eaax2746. Epub 2020 Apr 8.

Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Via Adamello 16, Milan 20139, Italy.

The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the rationale for the clinical use of LSD1 inhibitors. In acute promyelocytic leukemia (APL), pharmacological doses of retinoic acid (RA) induce differentiation of APL cells, triggering degradation of the PML-RAR oncogene. APL cells are resistant to LSD1 inhibition or knockout, but targeting LSD1 sensitizes them to physiological doses of RA without altering of PML-RAR levels, and extends survival of leukemic mice upon RA treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/sciadv.aax2746DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141832PMC

Dissecting the novel partners of nuclear c-Raf and its role in all-trans retinoic acid (ATRA)-induced myeloblastic leukemia cells differentiation.

Exp Cell Res 2020 Apr 10:111989. Epub 2020 Apr 10.

Department of Biomedical Sciences, Cornell University, Ithaca, NY, 14853, USA. Electronic address:

All-trans retinoic acid (ATRA) is an anti-cancer differentiation therapy agent effective for acute promyelocytic leukemia (APL) but not acute myeloid leukemia (AML) in general. Using the HL-60 human non-APL AML model where ATRA causes nuclear enrichment of c-Raf that drives differentiation and G1/G0 cell cycle arrest, we now observe that c-Raf in the nucleus showed novel interactions with several prominent regulators of the cell cycle and cell differentiation. One is cyclin-dependent kinase 2 (Cdk2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2020.111989DOI Listing

Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.

J Oncol Pharm Pract 2020 Apr 11:1078155220915764. Epub 2020 Apr 11.

School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155220915764DOI Listing

Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.

Med Oncol 2020 Apr 10;37(5):48. Epub 2020 Apr 10.

Adult Hemato-Lymphoid Disease Management Group, Tata Memorial Hospital, Mumbai, 400012, India.

Therapy-related acute leukemias (t-ALs) represent approximately 10-20% of all acute leukemias, are frequently resistant to chemotherapy, and are associated with guarded outcomes. The national comprehensive cancer network data suggest that t-AL cases are diagnosed at increasing rates in breast cancer patients treated with chemotherapeutic agents targeting topoisomerase II. Two cases of BRCA1-mutated ovarian and breast carcinoma who developed therapy-related APL and ALL, respectively, following topoisomerase II-directed therapy were characterized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-020-01371-zDOI Listing
April 2020
2.058 Impact Factor

Promyelocytic Blast Crisis of Chronic Myeloid Leukemia in a Patient Undergoing Therapy with a Tyrosine Kinase Inhibitor.

Cureus 2020 Mar 9;12(3):e7217. Epub 2020 Mar 9.

Hematology/Oncology, Cooper University Hospital, Camden, USA.

A 58-year-old male with the chronic phase of chronic myeloid leukemia (CML), treated with a tyrosine kinase inhibitor (TKI), bosutinib, since the past two years, presented with bright red bleeding per rectum and disseminated intravascular coagulation. A bone marrow biopsy reverse transcription-polymerase chain reaction revealed a promyelocytic blast crisis, with leukemic cells displaying both  and α chimeric genes. Cytogenetic studies revealed translocations of both t(15;17) and t(9;22). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141802PMC

Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.

J Geriatr Oncol 2020 Apr 6. Epub 2020 Apr 6.

University Hospital Fundacion Jimenez Diaz, Madrid, Spain.

Approximately one third of patients diagnosed with acute promyelocytic leukemia (APL) are above the age of sixty. It is important to ensure older adults receive optimal diagnosis and management since this subtype of acute myeloid leukemia - given appropriate treatment - is highly curable with lower risk of adverse events compared to other types of leukemia. Historically, older age has been a risk factor for early death and poorer overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2020.03.019DOI Listing

Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia.

EBioMedicine 2020 Apr 6;54:102678. Epub 2020 Apr 6.

University Hospital Tübingen, Dept. of Hematology, Oncology, clinical Immunology and Rheumatology, Otfried-Müller-Straße 10, BB West, Rooms 585-587, 72076 Tübingen, Germany; Clinic of Medical Oncology and Hematology, Cantonal Hospital St. Gallen (KSSG), Switzerland.

Background: Overriding the differentiation blockage in acute myeloid leukemia (AML) is the most successful mode-of-action in leukemia therapy - now curing the vast majority of patients with acute promyelocytic leukemia (APL) using all-trans retinoic acid (ATRA)-based regimens. Similar approaches in other leukemia subtypes, such as IDH1/2-mutated AML, are under active investigation. We herein present successful release of the differentiation blockage upon treatment with the natural (-)-Δ-Tetrahydrocannabinol isomer dronabinol in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2020.102678DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139116PMC

Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.

Ann Hematol 2020 May 8;99(5):973-982. Epub 2020 Apr 8.

Department of Hematology, Leukemia Research Institute, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-Gu, Seoul, Republic of Korea.

In this study, we investigated the safety and efficacy of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL). The patients had been classified as unfit to receive anthracycline-based chemotherapy due to high-risk factors for early death. Twenty-five patients with APL receiving ATO/ATRA between 2007 and 2018 were divided into 3 groups as follows: elderly patients (age ≥ 70 years) with poor performance status (32%); patients with severe active infections at diagnosis (56%); and patients with multiple significant comorbidities (24%) who were unfit for conventional chemotherapy, regardless of age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04010-9DOI Listing
May 2020
2.634 Impact Factor

Treatment Outcome and the Genetic Characteristics of Acute Promyelocytic Leukemia in Children in Poland From 2005 to 2018.

Front Pediatr 2020 20;8:86. Epub 2020 Mar 20.

Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.

The aim of the study was to analyze the treatment outcome and genetic characteristics of acute promyelocytic leukemia (APL) in children in Poland from 2005 to 2018. All 41 patients diagnosed with APL in Poland during the analysis period were eligible for the study. In period I (2005-2015), 33 patients were treated with chemotherapy and all-trans retinoic acid (ATRA), and in period II (2015-2018), 3 patients (high risk) received induction chemotherapy with ATRA and arsenic trioxide (ATO), and 5 patients (standard risk) received ATRA and ATO without chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2020.00086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100382PMC